---
figid: PMC5755720__ganc-08-746-g001
figtitle: ERBB signaling in CTCs of ovarian cancer and glioblastoma
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC5755720
filename: ganc-08-746-g001.jpg
figlink: /pmc/articles/PMC5755720/figure/F1/
number: F1
caption: A. Schema representing the migration of circulating tumor cells into the
  bloodstream. B. An illustration showing ERBB signaling pathway in circulating tumor
  cells. ERBB receptors undergo homo or hetero dimerization, then subsequent trans
  or auto phosphorylation after binding to the respective ligands like epidermal growth
  factor (EGF), transforming growth factor - alpha (TGF-α) or neuregulin (NRG1) as
  indicated. ERBB2 binds no ligand with high affinity, and ERBB3 homodimers are catalytically
  inactive due to the lack of kinase domains. Once phosphorylated and activated, receptors
  initiate recruitment and binding of adaptor proteins via SH2 domains, thereby activating
  downstream-signaling pathways that lead to the activation of various transcription
  factors required for survival and resistance to apoptosis.
papertitle: ERBB signaling in CTCs of ovarian cancer and glioblastoma.
reftext: Anjali Geethadevi, et al. Genes Cancer. 2017 Nov;8(11-12):746-751.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9748209
figid_alias: PMC5755720__F1
figtype: Figure
redirect_from: /figures/PMC5755720__F1
ndex: 817cb785-dec1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5755720__ganc-08-746-g001.html
  '@type': Dataset
  description: A. Schema representing the migration of circulating tumor cells into
    the bloodstream. B. An illustration showing ERBB signaling pathway in circulating
    tumor cells. ERBB receptors undergo homo or hetero dimerization, then subsequent
    trans or auto phosphorylation after binding to the respective ligands like epidermal
    growth factor (EGF), transforming growth factor - alpha (TGF-α) or neuregulin
    (NRG1) as indicated. ERBB2 binds no ligand with high affinity, and ERBB3 homodimers
    are catalytically inactive due to the lack of kinase domains. Once phosphorylated
    and activated, receptors initiate recruitment and binding of adaptor proteins
    via SH2 domains, thereby activating downstream-signaling pathways that lead to
    the activation of various transcription factors required for survival and resistance
    to apoptosis.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGF
  - PTEN
  - JAK2
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - STAT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K1
  - MAP2K2
  - MTOR
  - MAPK3
  - MAPK1
  - EPHB1
  - KCNH8
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MYC
  - EGR1
  - EGR2
  - EGR3
  - EGR4
  - JUN
  - JUNB
  - JUND
  - EGFR
  - CD80
  - NMBR
  - MBOAT7
  - ERBB2
  - NRG1
  - NRG2
  - NRG3
  - NRG4
  - ERBB3
  - ERBB4
  - Cancer
  - Lung cancer
  - Noonan syndrome
---
